1. Home
  2. AVDL vs CHY Comparison

AVDL vs CHY Comparison

Compare AVDL & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • CHY
  • Stock Information
  • Founded
  • AVDL 2015
  • CHY 2003
  • Country
  • AVDL Ireland
  • CHY United States
  • Employees
  • AVDL N/A
  • CHY N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • CHY Investment Managers
  • Sector
  • AVDL Health Care
  • CHY Finance
  • Exchange
  • AVDL Nasdaq
  • CHY Nasdaq
  • Market Cap
  • AVDL 784.6M
  • CHY 792.1M
  • IPO Year
  • AVDL 1996
  • CHY N/A
  • Fundamental
  • Price
  • AVDL $9.11
  • CHY $10.37
  • Analyst Decision
  • AVDL Strong Buy
  • CHY
  • Analyst Count
  • AVDL 6
  • CHY 0
  • Target Price
  • AVDL $18.17
  • CHY N/A
  • AVG Volume (30 Days)
  • AVDL 1.3M
  • CHY 128.3K
  • Earning Date
  • AVDL 05-07-2025
  • CHY 01-01-0001
  • Dividend Yield
  • AVDL N/A
  • CHY 10.11%
  • EPS Growth
  • AVDL N/A
  • CHY N/A
  • EPS
  • AVDL N/A
  • CHY N/A
  • Revenue
  • AVDL $194,450,000.00
  • CHY N/A
  • Revenue This Year
  • AVDL $55.11
  • CHY N/A
  • Revenue Next Year
  • AVDL $30.13
  • CHY N/A
  • P/E Ratio
  • AVDL N/A
  • CHY N/A
  • Revenue Growth
  • AVDL 252.64
  • CHY N/A
  • 52 Week Low
  • AVDL $6.38
  • CHY $9.97
  • 52 Week High
  • AVDL $17.30
  • CHY $12.16
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 53.96
  • CHY 53.28
  • Support Level
  • AVDL $8.77
  • CHY $10.20
  • Resistance Level
  • AVDL $9.31
  • CHY $10.43
  • Average True Range (ATR)
  • AVDL 0.41
  • CHY 0.13
  • MACD
  • AVDL -0.04
  • CHY -0.02
  • Stochastic Oscillator
  • AVDL 53.60
  • CHY 45.95

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About CHY Calamos Convertible and High Income Fund

Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.

Share on Social Networks: